Morningstar® Stock Report™

中國生物製藥有限公司 01177

Gewinnmarge (% des Umsatzes)
20192020202120222023
Ertrag100,00%100,00%100,00%100,00%100,00%
Betriebskosten20,33%21,92%19,85%20,14%19,05%
Bruttogewinn79,67%78,08%80,15%79,86%80,95%
Vertriebsgemeinkosten49,14%49,18%47,29%43,65%42,24%
Forschung und Entwicklung----16,81%
Umsatzrendite21,01%18,20%16,17%20,97%22,08%
Net Int, Inc and Other44,05%39,40%85,31%41,05%42,73%
EBIT Marge23,04%21,20%69,14%20,08%20,65%
Ertragskraft
20192020202120222023
Steuersatz3,67%2,84%7,29%2,70%3,04%
Nettomarge11,17%11,72%54,38%8,84%8,90%
Gesamtkapitalrendite5,015,2526,223,713,98
Financial Leverage1,872,822,002,152,09
Eigenkapitalsrendite8,9711,5860,067,708,45